Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_assertion type Assertion NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_head.
- NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_assertion description "[Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_provenance.
- NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_assertion evidence source_evidence_literature NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_provenance.
- NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_assertion SIO_000772 21245420 NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_provenance.
- NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_assertion wasDerivedFrom befree-20150227 NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_provenance.
- NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_assertion wasGeneratedBy ECO_0000203 NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_provenance.